Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml

Journal of Urology

Volumn 173, Issue 4, 2005, Pages 1116-1120

  Kundu, Shilajit D ^a   Grubb, Robert L ^a   Roehl, Kimberly A ^a   Antenor, Jo Ann V ^a   Han, Misop ^a   Catalona, William J ^a  

^a Department of Urology ^*

Author keywords

Mass screening; Prostate; Prostate specific antigen; Prostatic neoplasms; Risk

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW;

EID: 15044349594     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000155460.20581.a4     Document Type: Article

References (18)

1. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1999. CA Cancer J Clin, 49: 8, 1999
2. Crawford, E. D.: Epidemiology of prostate cancer. Urology, suppl., 62: 3, 2003
3. Cancer Facts and Figures 2003. Atlanta: American Cancer Society, 2003
4. Smith, R. A., Cokkinides, V., Eyre, H. J. and American Cancer Society: American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin, 53: 27, 2003
5. Carroll, P., Coley, C., McLeod, D., Schellhammer, P., Sweat, G., Wasson, J. et al: Prostate-specific antigen best practice policy. Part I: early detection and diagnosis of prostate cancer. Urology, 57: 217, 2001
6. Chu, K. C., Tarone, R. E. and Freeman, H. P.: Trends in prostate cancer mortality among black men and white men in the United States. Cancer, 97: 1507, 2003
7. Gann, P. H., Hennekens, C. H. and Stampfer, M. J.: A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA, 273: 289, 1995
8. Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A., Schroder, F. H. et al: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst, 95: 868, 2003
9. Ross, K. S., Carter, H. B., Pearson, J. D. and Guess, H. A.: Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA, 284: 1399, 2000
10. Crawford, D., Chia, D., Andriole, G. L., Reding, D., Gelmann, E. P., Gohogan, J. K. et al: PSA testing interval, reduction in screening intervals: data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. J Urol, suppl., 167: 99, abstract 397, 2002
11. Hoedemaeker, R. F., van der Kwast, T. H., Boer, R., de Koning, H. J., Roobol, M., Vis, A. N. et al: Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst, 93: 1153, 2001
12. D'Amico, A. V., Chen, M. H., Roehl, K. A. and Catalona, W. J.: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med, 351: 125, 2004
13. Carter, H. B., Epstein, J. I., Chan, D. W., Fozard, J. L. and Pearson, J. D.: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA, 277: 1456, 1997
14. Epstein, J. I., Partin, A. W., Sauvageot, J. and Walsh, P. C.: Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol, 20: 286, 1996
15. Yao, S.-L. and Lu-Yao, G.: Interval after prostate specific antigen testing and subsequent risk of incurable prostate cancer. J Urol, 166: 861, 2001
16. Postma, R., Roobol, M., Schroder, F. H. and van der Kwast, T. H.: Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Cancer, 100: 968, 2004
17. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA, 271: 368, 1994
18. Carter, H. B.: Prostate cancers in men with low PSA levels - must we find them? N Engl J Med, 350: 2292, 2004